Latest stories on VTGN
VistaGen Stockholders Reaffirm Board, Governance and Oversight
TipRanks50 · neutralgeneral
Vistagen Therapeutics, Inc. (VTGN) files 8-K
SEC 8-K50 · neutralgeneral
Vistagen to Present at Psych Congress 2026
Business Insider56 · neutralproduct/pr
Vistagen Therapeutics, Inc. (VTGN) files 8-K
SEC 8-K50 · neutralgeneral
VistaGen Therapeutics GAAP EPS of -$0.30 beats by $0.06, revenue of $1.48M beats by $1.31M
Seeking Alpha63 · neutralearnings
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
GlobeNewswire56 · neutralearnings
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
StockTitan50 · neutralearnings
Vistagen Therapeutics, Inc. (VTGN) files 8-K
SEC 8-K50 · neutralgeneral
Vistagen Announces Topline Results From Fasedienol Repeat Dose Study
The Fly63 · neutralearnings
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
StockTitan63 · neutralproduct/pr
Vistagen Therapeutics, Inc. (VTGN) files 8-K
SEC 8-K34 · bearishgeneral
SRX Global Acquires Stake in Vistagen Therapeutics
Yahoo Top63 · neutralm&a
SRX Global Takes a Strategic Stake in Vistagen Therapeutics—A Fresh Vote of Confidence in Neuroscience Innovation
MarketChameleon63 · neutralm&a
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
Business Insider63 · neutralm&a
VistaGen Therapeutics Appoints Douglas Williamson to Board
TipRanks55 · neutralgeneral
Vistagen Therapeutics, Inc. (VTGN) files 8-K
SEC 8-K50 · neutralgeneral
Vistagen Appoints Douglas J. Williamson to its Board of Directors
StockTitan55 · neutralgeneral
Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?
Yahoo Finance38 · neutralproduct/pr
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript
Seeking Alpha56 · neutralproduct/pr
This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals – But Retail Believes It’s Oversold, Says Won’t Panic-Sell
Stocktwits News32 · bearishearnings
VistaGen pivots fasedienol toward long-term anxiety treatment
TipRanks56 · neutralproduct/pr
Vistagen Therapeutics, Inc. (VTGN) files 8-K
SEC 8-K50 · neutralgeneral
Vistagen Therapeutics, Inc. (VTGN) files 8-K
SEC 8-K50 · neutralgeneral
Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth
TipRanks34 · bearishgeneral